Serum visfatin characteristic peak screening coronary heart disease study based on Raman spectroscopy

Area of Science:

• Biochemistry
• Spectroscopy
• Cardiovascular Research

Background:

• Serum visfatin, an adipokine, plays a role in metabolic regulation and inflammation.
• Coronary heart disease (CHD) is a leading cause of mortality worldwide.
• Biomarkers for early CHD detection are crucial for timely intervention.

Purpose of the Study:

• To investigate spectral differences in serum visfatin between CHD patients and healthy controls using Raman spectroscopy.
• To evaluate the potential of serum visfatin as a screening biomarker for CHD.

Main Methods:

• Serum samples from 60 CHD patients and 57 healthy individuals were analyzed using Raman spectroscopy.
• Characteristic spectral peaks of serum visfatin were identified and compared between groups.
• Statistical analysis was performed to determine the distinguishing power of specific peaks.

Main Results:

• Significant differences in Raman spectral peaks of serum visfatin were observed between CHD patients and healthy controls.
• Peaks at 850.95, 1265.92, 1336.99, 1446.48, 1603.83, and 1657.69 cm⁻¹ were stronger in CHD patients.
• Peaks at 1000.52, 1154.51, and 1515.53 cm⁻¹ were stronger in healthy individuals.
• Spectral peaks at 1265.92 and 1446.48 cm⁻¹ demonstrated a distinguishing effect between CHD patients and healthy controls.

Conclusions:

• Raman spectroscopy can differentiate serum visfatin profiles in CHD patients and healthy individuals.
• Specific visfatin spectral peaks hold potential as novel biomarkers for CHD screening.
• Further validation is warranted to establish serum visfatin's role in clinical CHD diagnostics.